Real world data of cabozantinib in patients with hepatocellular carcinoma: Focusing on dose setting and modification.

Cancer Med · 2024 · PMC11420626 · PMID 39315523

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

showed a trendp = 0.054so close (0.05 < p ≤ 0.1)

Patients who received RDI during 6 weeks ≥33.4% showed a trend toward longer median PFS ( p = 0.054).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.